Research programme: microbiota restoration therapy - Rebiotix

Drug Profile

Research programme: microbiota restoration therapy - Rebiotix

Alternative Names: RBX 6376; RBX 8225; RBX2477

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rebiotix
  • Class
  • Mechanism of Action Immunomodulators; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatic encephalopathy; Infections; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 11 Oct 2016 Rebiotix has patent protection for microbiota restoration therapy in USA, Australia and Canada
  • 20 Jul 2016 Preclinical trials in Hepatic encephalopathy in USA (unspecified route) (Rebiotix pipeline, July 2016)
  • 20 Jul 2016 Preclinical trials in Infections in USA (unspecified route) (Rebiotix pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top